CluenexHumana HUM
Humana scores average on business quality (4.7 of 10). Here is why, in plain words, and what our sealed record shows.
Why it matters
- What Humana does
Humana sells health insurance products, focusing heavily on Medicare Advantage plans for older adults who pay premiums for coordinated medical care. The company is cutting back certain Medicare Advantage offerings to protect margins amidst rising medical costs.
- What it does best
Humana dominates specialized senior healthcare through its massive Medicare Advantage membership base. This scale creates deep regional density that rivals struggle to match efficiently.
- The main risk
Medicare Advantage plan cuts threaten enrollment volume and top-line expansion as regulatory pressures mount.
Quality, check by check
Scored against its own industry, from company filings.
Operating margin sits at 2.4% and net margin at 0.9%, reflecting severe cost pressures. The business struggles to expand profitability as revenue scales.
Regulatory complexities and senior healthcare focus form its moat, locking in aging members. Operating margins sit in the sector bottom quartile at 2.4%.
Revenue grew 10.1% to $145.7B, powered by health plan enrollment. Growth remains decent but faces impending headwinds from planned plan reductions.
Debt-to-equity sits at 0.7x with interest coverage near 5.0x, leaving narrow room for error. Free cash flow dropped to $1.9B. The balance sheet is softening.
Insiders
Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.
No open market buys or unplanned sales by executives or directors.
Our sealed record on HUM
Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.
The first sealed verdicts appear here on Oct 11, 2026.
Questions
Humana scores average on the Cluenex quality check (4.7 of 10), measured against its own industry. Profitability is weak, moat fair, growth steady and financial health fair.
In the last 90 days of SEC Form 4 filings: No open market buys or unplanned sales by executives or directors.
Nov 6, 2026, before the open.
See HUM today
- Today's verdict on HUM, and why
- Fair value with cautious, base and optimistic cases
- The exact price that would change the verdict
- Which stocks each signal names, the night it fires
Cite this page: Cluenex, “Humana (HUM)”, https://cluenex.com/stocks/hum/, data as of Oct 10, 2026.